Q4 2017

Filed Jul 14, 2017 · 10-K · 105 days after period end · 0001185185-17-001544

Q4 2017 · 10-K

derived · Computed from the longer spans the company filed.

Revenue—

Net Income

-$788.26K

derivedN/M vs Q4 2016

EPS, diluted—Not derived. Share counts vary by quarter.

Operating Incomederived-$799,835N/M

Same quarter

Metric	Q4 2017derived from reported figures	Q4 2016derived from reported figures	Q4 2015derived from reported figures	Q4 2014derived from reported figures
Revenue	—	$1.37M	$2.26M	—
Net Income	-$788.26K	-$1.40M	-$1.94M	-$1.46M

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

IGC Pharma, Inc. · CIK 1326205 · Engraved from SEC EDGAR